10-Q: Vanda Pharmaceuticals Reports Wider Q3 Loss Amid R&D Surge

Vanda Pharmaceuticals reported a significantly wider net loss in the third quarter of 2025, driven by increased R&D and commercialization expenses, despite strong Fanapt sales growth.

Summary

• Net loss for Q3 2025 widened to $22.6 million, compared to $5.3 million for Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $79.3 million, significantly higher than $14.0 million for the same period in 2024.
• Total revenues for Q3 2025 increased by 18% to $56.3 million, up from $47.7 million in Q3 2024.
• Total revenues for the nine months ended September 30, 2025, increased by 9% to $158.9 million, from $145.6 million in the prior year period.
• Fanapt net product sales grew 31% in Q3 2025 to $31.2 million and 24% for the nine months to $84.1 million, driven by increased volume and the bipolar I disorder launch.
• HETLIOZ net product sales remained relatively flat in Q3 2025 at $18.0 million (1% increase) but decreased 3% for the nine months to $55.0 million due to lower volume and continued generic competition.
• PONVORY net product sales increased 20% in Q3 2025 to $7.0 million but decreased 7% for the nine months to $19.8 million due to a decrease in price net of deductions.
• Research and development expenses surged 34% in Q3 2025 to $22.6 million and 47% for the nine months to $80.3 million, primarily due to the imsidolimab license payment and Fanapt/Bysanti development programs.
• Selling, general and administrative expenses increased 60% in Q3 2025 to $60.3 million and 63% for the nine months to $175.0 million, driven by commercial launches for Fanapt (bipolar disorder) and PONVORY (RMS), including a direct-to-consumer campaign.
• Cash, cash equivalents, and marketable securities decreased to $293.8 million as of September 30, 2025, from $374.6 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $80.0 million, a significant increase from $13.9 million in the prior year period.

Sentiment

Score: 4

Explanation: The company experienced a substantial increase in net loss and operating expenses, leading to a significant cash burn. While Fanapt sales showed strong growth, HETLIOZ and PONVORY sales faced headwinds. The extensive legal battles and the potential for future revenue declines from generic competition and Medicare Part D changes present considerable financial and operational challenges, despite some positive regulatory developments.

Positives

• Strong growth in Fanapt net product sales (31% in Q3, 24% for 9 months) and total prescriptions (35% in Q3), driven by the bipolar I disorder launch.
• Successful direct-to-consumer campaign for Fanapt and PONVORY, increasing brand awareness.
• Agreement on a collaborative framework with the FDA for resolution of certain disputes regarding HETLIOZ and tradipitant, including expedited re-reviews.
• Positive ruling from the DC Circuit Court of Appeals in favor of the company against the FDA regarding HETLIOZ for jet lag disorder, remanding the case back to the FDA.
• Denial of Teva's motion to dismiss in the HETLIOZ false advertising lawsuit, allowing the company's lawsuit to proceed.
• Denial of motions for judgment on the pleadings by Teva and Apotex in HETLIOZ patent infringement lawsuit, allowing the company's lawsuit to proceed.
• The One Big Beautiful Bill Act (OBBBA) permanently eliminates the requirement to capitalize and amortize U.S.-based research and development expenditures, providing an option for full deduction in the period incurred.

Negatives

• Significantly wider net loss for both the three months ($22.6 million vs $5.3 million) and nine months ($79.3 million vs $14.0 million) ended September 30, 2025.
• Substantial increase in operating expenses, with R&D up 34% (Q3) and 47% (9 months), and SG&A up 60% (Q3) and 63% (9 months).
• Decrease in HETLIOZ net product sales for the nine months ended September 30, 2025, due to lower volume and continued generic competition.
• Decrease in PONVORY net product sales for the nine months ended September 30, 2025, due to a decrease in price net of deductions.
• Significant increase in net cash used in operating activities ($80.0 million for 9 months 2025 vs $13.9 million for 9 months 2024).
• Decline in cash, cash equivalents, and marketable securities from $374.6 million to $293.8 million.
• Medicare Part D benefit redesign is expected to result in higher discounts for the Medicare payor segment, potentially reducing future revenues.
• The Delaware District Court overruled the company's objections and granted the defendants' motion to dismiss Lanham Act claims in the HETLIOZ false advertising lawsuit against MSN/Amneal/Impax.
• The U.S. Court of Appeals for the Federal Circuit ruled against the company in the tradipitant Fast Track designation appeal, and the company has petitioned the U.S. Supreme Court for review.
• The Federal Claims Court ruled against the company in the trade secrets lawsuit against the federal government (FDA disclosure), which has been appealed.

Risks

• Ability to commercialize Fanapt, HETLIOZ, and PONVORY in existing and new markets, especially with generic competition for HETLIOZ.
• Uncertainty regarding FDA approvals for Bysanti, HETLIOZ (new indications), PONVORY (new indications), tradipitant, and imsidolimab.
• Continued reimbursement and patient access challenges due to third-party payor coverage.
• Dependence on third-party manufacturers for product supply.
• Ability to prepare, file, prosecute, defend, and enforce patent claims and other intellectual property rights, especially given ongoing litigation.
• Impact of public health crises, epidemics, pandemics, or similar events on business and operations.
• Limitations on the ability to utilize prior net operating losses and orphan drug/R&D credits.
• Potential for significant future revenue reversal for HETLIOZ due to inventory stocking at specialty pharmacies and generic competition.
• Variability in PONVORY net product sales due to a disputed amount of variable consideration.
• Ongoing legal proceedings, including patent infringement, false advertising, and challenges against FDA decisions, which could result in adverse outcomes, significant costs, and impact product commercialization.
• The conclusion about the appropriateness of the deferred tax asset valuation allowance could change if pretax losses continue or projections change, leading to a non-cash income tax expense.
• Need for additional capital to fund research, development, or commercial activities, which may not be available on acceptable terms or could dilute existing stockholders.

Future Outlook

Expects significant research and development expenses to continue as products are developed and the pipeline expands. Selling, general and administrative expenses may increase in future periods due to ongoing commercial launches. HETLIOZ net product sales may reflect lower unit sales due to reduction of elevated inventory levels at specialty pharmacy customers or may be variable, and may decline significantly due to continued generic competition. Revenues may decline in future periods due to the Medicare Part D program benefit redesign. Believes current cash, cash equivalents, and marketable securities, along with product sales, will be sufficient for at least the next 12 months. May need or desire additional capital through debt, equity, or alternative financing arrangements in the future. Results of operations will fluctuate due to commercialization success, R&D progress, clinical trial outcomes, regulatory approvals, and litigation.

Management Comments

• "We strive to advance novel approaches to bring important new medicines to market through responsible innovation."
• "We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products."
• "Our ability to generate meaningful product sales and achieve profitability largely depends on our level of success in commercializing Fanapt in the United States (U.S.), HETLIOZ in the U.S. and Europe and PONVORY in the U.S. and Canada, on our ability, alone or with others, to complete the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our products."
• "We expect to incur significant research and development expenses as we continue to develop our products and continue our efforts to expand our product pipeline."
• "Selling, general and administrative expenses may increase in future periods as a result of the ongoing commercial launches."
• "Based on our current operating plans... we believe that our cash, cash equivalents and marketable securities and cash received from product sales will be sufficient for at least the next 12 months."

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, intense competition, and complex regulatory pathways. Vanda Pharmaceuticals' increased R&D and SG&A expenses reflect the typical investment required for drug development and commercialization, especially for new product launches and expanded indications. The challenges faced by HETLIOZ due to generic competition and the Medicare Part D benefit redesign are common industry trends impacting established products. The company's extensive litigation against the FDA and generic manufacturers highlights the ongoing intellectual property and regulatory battles prevalent in the pharmaceutical sector. The collaborative framework with the FDA for dispute resolution could be a positive sign for navigating regulatory hurdles, which are a significant factor in the industry.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Ongoing patent infringement lawsuits against Teva Pharmaceuticals USA, Inc. and Apotex Inc. regarding generic versions of HETLIOZ (U.S. Patent Nos. 11,285,129 and 11,918,556), with a trial scheduled for August 3, 2026.
• Ongoing lawsuit against Teva challenging its advertising and marketing practices for generic HETLIOZ, alleging promotion beyond approved labeling.
• Appeal to the U.S. Court of Appeals for the District of Columbia Circuit challenging the FDA's approval of Teva's generic HETLIOZ ANDA due to non-compliance with Braille labeling requirements.
• Ongoing lawsuit against the FDA challenging the approval of MSN Pharmaceuticals Inc.'s generic HETLIOZ ANDA, citing faulty bioequivalence studies and Appointments Clause claims.
• Appeal to the U.S. Court of Appeals for the D.C. Circuit regarding the dismissal of Lanham Act claims in a false advertising and unfair competition lawsuit against MSN, Amneal Pharmaceuticals, Inc., and Impax Laboratories LLC concerning HETLIOZ.
• Ongoing Hatch-Waxman lawsuit against MSN regarding generic HETLIOZ LQ, asserting infringement of multiple patents, with a trial rescheduled for September 14, 2026.
• Nine outstanding Freedom of Information Act (FOIA) lawsuits against the FDA to compel production of records related to various regulatory decisions and communications.
• Petition for a writ of certiorari filed with the U.S. Supreme Court to review the denial of Fast Track designation for tradipitant.
• The U.S. Court of Appeals for the D.C. Circuit ruled in favor of the company against the FDA, setting aside the FDA's refusal to hold a hearing on the sNDA for HETLIOZ in jet lag disorder and remanding the case.
• Appeal to the U.S. Court of Appeals for the Federal Circuit regarding a Federal Claims Court ruling against the company in a lawsuit alleging uncompensated taking and misuse of trade secrets by the FDA.
• Lawsuit against the FDA challenging the complete response letter and 60-day filing regulations for HETLIOZ in insomnia, with proceedings stayed until January 2026.
• Ongoing lawsuit against the FDA challenging the authority of FDA decision-makers under the Appointments Clause regarding the tradipitant NDA for gastroparesis.
• Lawsuit against the FDA challenging the complete response letter and 60-day filing regulations for tradipitant to prevent vomiting induced by motion, with proceedings stayed until January 2026.
• Petition for review in the U.S. Court of Appeals for the DC Circuit seeking review of the FDA's final order refusing to hold a hearing or approve the sNDA for HETLIOZ in insomnia.
• A shareholder lawsuit (Steamfitters Local 449 Pension Fund v. Mihael H. Polymeropoulos, et al.) was dismissed with prejudice after the company amended its Rights Agreement, but the plaintiff was awarded $2.0 million in attorneys' fees and expenses.

Stakeholder Impact

• Shareholders: Negative impact due to increased net losses, significant cash burn, and declining cash reserves. Potential for dilution if additional capital is raised through equity. Uncertainty from ongoing litigation.
• Patients: Potential for new treatment options with ongoing clinical trials and regulatory submissions for Bysanti, tradipitant, and imsidolimab. Continued availability of Fanapt, HETLIOZ, and PONVORY.
• Employees: Continued investment in R&D and commercial infrastructure suggests stable or growing employment opportunities, particularly in sales and development.
• Customers (Wholesalers, Specialty Pharmacies, Distributors): Continued business with the company's commercial products. Potential for variability in HETLIOZ sales due to inventory levels and generic competition.
• Regulatory Bodies (FDA): Ongoing engagement through numerous lawsuits and collaborative frameworks, indicating a complex relationship and significant regulatory scrutiny.

Next Steps

• Results for tradipitant clinical study in prevention of vomiting induced by GLP-1 analog expected in Q4 2025.
• FDA to conduct expedited re-review of tradipitant motion sickness partial clinical hold by November 26, 2025.
• FDA to continue review of tradipitant NDA for motion sickness with PDUFA target action date of December 30, 2025.
• FDA to conduct expedited re-review of HETLIOZ sNDA for jet lag disorder by January 7, 2026.
• FDA review of Bysanti NDA for bipolar I disorder and schizophrenia continues with PDUFA target action date of February 21, 2026.
• Bysanti Phase III clinical study for MDD is enrolling patients, with results expected in 2026.
• Imsidolimab Biologics License Application (BLA) in GPP expected to be submitted to the FDA in Q4 2025.
• Phase III study of iloperidone LAI for schizophrenia relapse-prevention is enrolling patients.
• Clinical study of iloperidone LAI in treatment-resistant hypertension plans to begin enrolling patients soon.
• Trial for HETLIOZ 129 Patent and 556 Patent infringement lawsuits scheduled to begin on August 3, 2026.
• Trial for HETLIOZ LQ patent infringement lawsuit scheduled to begin on September 14, 2026.
• HETLIOZ Germany royalty payments to BMS will end in October 2026.
• Fanapt U.S. royalty payments to Sanofi will end in November 2026.

Key Dates

Recommendation

While Fanapt shows strong sales growth and there are positive developments in some regulatory disputes, the company's financial performance is concerning, with significantly widened losses and increased cash burn. The extensive and costly litigation, coupled with the impact of generic competition on HETLIOZ and changes in Medicare Part D, creates substantial uncertainty. The need for potential future capital raises also poses a risk of dilution. Given the mix of growth in one key product and significant financial and legal headwinds, a "hold" recommendation is appropriate, advising investors to monitor the outcomes of ongoing clinical trials, regulatory decisions, and litigation, as well as the company's ability to manage its cash flow and achieve profitability.

Keywords

Biopharmaceutical, Vanda Pharmaceuticals, Fanapt, HETLIOZ, PONVORY, Tradipitant, Bysanti, Imsidolimab, Schizophrenia, Bipolar I disorder, Non-24-Hour Sleep-Wake Disorder, Smith-Magenis syndrome, Multiple Sclerosis, Gastroparesis, Motion Sickness, Generalized Pustular Psoriasis, Drug development, Clinical trials, FDA approval, SEC filing, 10-Q, Pharmaceuticals, Biotech, Drug sales, R&D expenses, Commercialization, Patent litigation, Regulatory challenges